Investigating how certain kidney cells can be targeted to prevent chronic kidney disease after acute injury
Targeting Renal Tubular Epithelial Progenitors in AKI to CKD transition
This study is looking at special kidney cells that could help heal your kidneys after an injury, and it aims to find new ways to make these cells work better so that you can avoid long-term kidney problems.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Duke University NIH-funded |
| Lab location | 1 site (Durham, United States) |
| Project ID | NIH-10866374 on NIH RePORTER |
What this research studies
This research focuses on understanding how specific kidney cells, known as Sox9-progenitors, can be targeted to improve kidney repair after acute kidney injury (AKI). The study aims to uncover the molecular mechanisms that lead to the dysfunction of these cells, particularly how oxidative stress and a process called ferroptosis contribute to their failure. By identifying new therapeutic strategies to enhance the regenerative capacity of these cells, the research seeks to prevent the progression from AKI to chronic kidney disease (CKD). Patients may benefit from potential new treatments that could improve kidney function and reduce the risk of CKD.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals who have experienced acute kidney injury and are at risk of developing chronic kidney disease.
Not a fit: Patients with chronic kidney disease not related to acute kidney injury may not receive benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to new therapies that enhance kidney repair and prevent the progression to chronic kidney disease.
How similar studies have performed: Other research has shown promise in targeting cellular mechanisms for kidney repair, but this specific approach focusing on Sox9-progenitors and ferroptosis is relatively novel.
Where this research is happening
Durham, United States
- Duke University — Durham, United States (Active)
Researchers
- Principal investigator: Souma, Tomokazu — Duke University
- Study coordinator: Souma, Tomokazu
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.